Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
نویسندگان
چکیده
منابع مشابه
Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma
Approaches aimed at enhancement of the tumor specific response have provided proof for the rationale of immunotherapy in cancer, both in animal models and in humans. Ipilimumab, an anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) antibody, is a new generation immunotherapeutic agent that has shown activity in terms of disease free and overall survival in metastatic melanoma patients. Its use was ...
متن کاملImmune modulation in melanoma and advanced cancer therapy: anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibodies.
Two fully human monoclonal antibodies (mAbs) that target cytotoxic T lymphocyte-associated antigen 4 (CTLA4), tremelimumab and ipilimumab, are in clinical development for the treatment of advanced cancers. The investigational agents enhance T-cell activation and are hypothesized to generate antitumor immunity. Clinical data have shown that treatment with an anti-CTLA4 mAb is tolerable in most p...
متن کاملCytotoxic T-lymphocyte-associated antigen-4.
Cancer immunotherapy relies on the ability of the immune system to target tumor-specific antigens to generate an immune response. This initial response requires both binding of the MHC/antigen peptide to T-cell receptor complex, along with a second costimulatory signal created by the binding of CD28 on the T cell, with B7 located on the antigen-presenting cell. Regulatory checkpoints, such as c...
متن کاملThe monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
BACKGROUND Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor cells. Ipilimumab is a monoclonal antibody directed against CTLA-4. OBJECTIVE This review describes the basic mechanism of ipilimumab and discusses data available to date with regards to its safety and efficacy profile. METHODS Data from clinical trials including abstr...
متن کاملThe clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies.
The recent cloning and identification of a variety of regulatory and counter-regulatory molecules on T cells and antigen presenting cells has led to the development of antibodies and other molecules that either stimulate or abrogate these immune functions. Patients with autoimmune disease, graft rejection and cancer might benefit from the ability to manipulate immune regulatory pathways. The fi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical, Cosmetic and Investigational Dermatology
سال: 2013
ISSN: 1178-7015
DOI: 10.2147/ccid.s24246